

Almirall's Annual General Meeting approves a dividend of 0.29 euros per share

- **The pharmaceutical company allocates over 47 million euros to shareholder dividend payments**

Barcelona, 6 May 2011.- Almirall, the international pharmaceutical company located in Spain, approved in its Annual General Meeting the awarding of 47.441.600 euros as dividend payments to its shareholders; 40% of its 2010 net income and within the highest range of its dividend payment policy. A gross dividend of around 0.29 euros per share will therefore be paid out by 1 June.

The Chairman and Chief Executive Officer, Jorge Gallardo, states: *"Once again we are pleased to be able to share Almirall's results with our shareholders in line with forecasts. These have come from a strong, forward-looking business strategy, despite the complexity of the economic environment and the pharmaceutical sector's adverse circumstances"*.

Points on the agenda included examination and approval of 2010's financial statements when Almirall obtained a net income of 118.6 million euros. Normalized Net Income totalled 136.7 million euros which was fully aligned with Almirall's guidance and expectations.

The 2010 EBITDA totalled 216.3 million euros. Net sales rose to 882.4 million euros; other income, which remained a key contributor and reflection of Almirall's business model, went up to 119.7 million euros (11% more than the previous year).

The company remains committed to research and development, and as such allocated resources of 144.9 million euros in 2010; 16.4% of its income compared to 13.1% the previous year.

Extensive R&D pipeline

Innovation is one of Almirall's key growth drivers. Its current pipeline is the most extensive in Almirall's history. Almirall currently has five R&D projects about to start or already in phase III and expects to file another two products in 2011: acridinium bromide, to treat chronic obstructive pulmonary disease, and linaclotide, for irritable bowel syndrome with constipation, for which there is no specific treatment approved by the European Medicines Agency .

Furthermore, after the approval of *Sativex* for spasticity in multiple sclerosis, which has just been launched in Spain, two new phase III studies for future use in cancer pain have recently got underway in the USA and Europe.

Almirall

Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing. Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), gastrointestinal disorders, psoriasis and other dermatological conditions.

Almirall's products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 12 affiliates.

For further information please visit the website at: www.almirall.com

**Para más información:
Ketchum/SEIS**

Sonia San Segundo/Patricia Mansilla
sonia.sansegundo@ketchum.com
Tel.: 00 34 91 788 32 00